Article Details

CD19 CAR-T Cells by Shanghai YaKe Biotechnology for Primary Mediastinal B-Cell Lymphoma

Retrieved on: 2024-01-22 19:25:11

Tags for this article:

Click the tags to see associated articles and topics

CD19 CAR-T Cells by Shanghai YaKe Biotechnology for Primary Mediastinal B-Cell Lymphoma. View article details on HISWAI: https://www.pharmaceutical-technology.com/uncategorized/cd19-car-t-cells-shanghai-yake-biotechnology-primary-mediastinal-b-cell-lymphoma-likelihood-of-approval/

Excerpt

CD19 CAR-T Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.

Article found on: www.pharmaceutical-technology.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up